JPWO2022147026A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022147026A5 JPWO2022147026A5 JP2023539810A JP2023539810A JPWO2022147026A5 JP WO2022147026 A5 JPWO2022147026 A5 JP WO2022147026A5 JP 2023539810 A JP2023539810 A JP 2023539810A JP 2023539810 A JP2023539810 A JP 2023539810A JP WO2022147026 A5 JPWO2022147026 A5 JP WO2022147026A5
- Authority
- JP
- Japan
- Prior art keywords
- pbmcs
- binds
- antibody
- combination
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 114
- 238000000034 method Methods 0.000 claims description 75
- 239000000203 mixture Substances 0.000 claims description 67
- 241000701806 Human papillomavirus Species 0.000 claims description 45
- 239000000427 antigen Substances 0.000 claims description 39
- 102000036639 antigens Human genes 0.000 claims description 39
- 108091007433 antigens Proteins 0.000 claims description 39
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 32
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 32
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 28
- 239000012595 freezing medium Substances 0.000 claims description 28
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 22
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 22
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 20
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 20
- 210000004027 cell Anatomy 0.000 claims description 19
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 16
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 16
- 238000009472 formulation Methods 0.000 claims description 16
- 229960005386 ipilimumab Drugs 0.000 claims description 12
- 229960003852 atezolizumab Drugs 0.000 claims description 10
- 229960003301 nivolumab Drugs 0.000 claims description 10
- 229940046166 oligodeoxynucleotide Drugs 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 8
- 229940124060 PD-1 antagonist Drugs 0.000 claims description 7
- 229940123751 PD-L1 antagonist Drugs 0.000 claims description 7
- 239000005557 antagonist Substances 0.000 claims description 7
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 6
- 239000000556 agonist Substances 0.000 claims description 6
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 6
- 210000001616 monocyte Anatomy 0.000 claims description 6
- 210000000822 natural killer cell Anatomy 0.000 claims description 6
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 230000001143 conditioned effect Effects 0.000 claims description 5
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 108010075704 HLA-A Antigens Proteins 0.000 claims description 4
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 4
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 4
- 229960002621 pembrolizumab Drugs 0.000 claims description 4
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 claims description 3
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 claims description 3
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims description 3
- 102000006992 Interferon-alpha Human genes 0.000 claims description 3
- 108010047761 Interferon-alpha Proteins 0.000 claims description 3
- GUVMFDICMFQHSZ-UHFFFAOYSA-N N-(1-aminoethenyl)-1-[4-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[hydroxy-[[3-[hydroxy-[[3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-[[[2-[[[2-[[[5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[5-(4-amino-2-oxopyrimidin-1-yl)-2-[[hydroxy-[2-(hydroxymethyl)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-2-yl]-5-methylimidazole-4-carboxamide Chemical compound CC1=C(C(=O)NC(N)=C)N=CN1C1OC(COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)CO)C(OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)O)C1 GUVMFDICMFQHSZ-UHFFFAOYSA-N 0.000 claims description 3
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 claims description 3
- 229940044606 RIG-I agonist Drugs 0.000 claims description 3
- 229940044665 STING agonist Drugs 0.000 claims description 3
- 102100024324 Toll-like receptor 3 Human genes 0.000 claims description 3
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims description 3
- 239000006285 cell suspension Substances 0.000 claims description 3
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims description 3
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 229940044655 toll-like receptor 9 agonist Drugs 0.000 claims description 3
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 2
- 241000341655 Human papillomavirus type 16 Species 0.000 claims description 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 2
- 230000000306 recurrent effect Effects 0.000 claims description 2
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 claims 2
- 230000003750 conditioning effect Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 102000011786 HLA-A Antigens Human genes 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 206010061424 Anal cancer Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063131504P | 2020-12-29 | 2020-12-29 | |
| US63/131,504 | 2020-12-29 | ||
| US202163190194P | 2021-05-18 | 2021-05-18 | |
| US63/190,194 | 2021-05-18 | ||
| US202163249739P | 2021-09-29 | 2021-09-29 | |
| US63/249,739 | 2021-09-29 | ||
| US202163278788P | 2021-11-12 | 2021-11-12 | |
| US63/278,788 | 2021-11-12 | ||
| PCT/US2021/065362 WO2022147026A1 (en) | 2020-12-29 | 2021-12-28 | METHODS FOR TREATING CANCERS WITH MODIFIED PBMCs |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024503278A JP2024503278A (ja) | 2024-01-25 |
| JPWO2022147026A5 true JPWO2022147026A5 (https=) | 2024-12-25 |
| JP2024503278A5 JP2024503278A5 (https=) | 2024-12-25 |
Family
ID=80001316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023539810A Pending JP2024503278A (ja) | 2020-12-29 | 2021-12-28 | 修飾ｐｂｍｃを用いたがんの治療方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20220233677A1 (https=) |
| EP (1) | EP4271711A1 (https=) |
| JP (1) | JP2024503278A (https=) |
| CA (1) | CA3203696A1 (https=) |
| TW (1) | TW202241466A (https=) |
| WO (1) | WO2022147026A1 (https=) |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107058101B (zh) | 2011-10-17 | 2021-06-01 | 麻省理工学院 | 细胞内传递 |
| EP3033184B1 (en) | 2013-08-16 | 2021-03-31 | Massachusetts Institute of Technology | Selective delivery of material to cells |
| JP7523203B2 (ja) | 2014-10-31 | 2024-07-26 | マサチューセッツ インスティテュート オブ テクノロジー | 生体分子の免疫細胞への送達 |
| SG10201912910PA (en) | 2015-07-09 | 2020-02-27 | Massachusetts Inst Technology | Delivery of materials to anucleate cells |
| ES2930017T3 (es) | 2015-09-04 | 2022-12-05 | Sqz Biotechnologies Co | Suministro intracelular de biomoléculas mediado por una superficie con poros |
| KR102490952B1 (ko) | 2016-05-03 | 2023-01-19 | 에스큐지 바이오테크놀로지스 컴퍼니 | 관용을 유도하는 생체분자의 세포내 전달 |
| JP7602702B2 (ja) | 2016-05-03 | 2024-12-19 | ステムセル テクノロジーズ カナダ インコーポレーテッド | 寛容性を誘導するための生体分子の細胞内送達 |
| EP3765068A2 (en) | 2018-03-12 | 2021-01-20 | SQZ Biotechnologies Company | Intracellular delivery of biomolecules to modify immune response |
| US12599656B2 (en) * | 2018-03-12 | 2026-04-14 | Stemcell Technologies Canada Inc. | Methods for treating HPV-associated diseases |
| KR20210070338A (ko) | 2018-10-04 | 2021-06-14 | 에스큐지 바이오테크놀로지스 컴퍼니 | 항원 제시 세포 기능을 증진시키기 위한 생체분자의 세포내 전달 |
| WO2020154696A1 (en) | 2019-01-25 | 2020-07-30 | Sqz Biotechnologies Company | Anucleate cell-derived vaccines |
| CA3131701A1 (en) * | 2019-02-28 | 2020-09-03 | Sqz Biotechnologies Company | Delivery of biomolecules to pbmcs to modify an immune response |
| WO2021123832A1 (en) * | 2019-12-20 | 2021-06-24 | Instil Bio (Uk) Limited | Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof |
| KR20230079066A (ko) * | 2020-09-02 | 2023-06-05 | 에스큐지 바이오테크놀로지스 컴퍼니 | 유핵 세포를 사용하여 단백질에 대한 hla-불문 면역 반응을 자극하는 방법 |
| US20220296691A1 (en) * | 2020-12-29 | 2022-09-22 | Sqz Biotechnologies Company | Methods for treating cancer with activating antigen carriers |
-
2021
- 2021-12-28 TW TW110149082A patent/TW202241466A/zh unknown
- 2021-12-28 CA CA3203696A patent/CA3203696A1/en active Pending
- 2021-12-28 US US17/563,866 patent/US20220233677A1/en not_active Abandoned
- 2021-12-28 EP EP21848092.9A patent/EP4271711A1/en active Pending
- 2021-12-28 JP JP2023539810A patent/JP2024503278A/ja active Pending
- 2021-12-28 WO PCT/US2021/065362 patent/WO2022147026A1/en not_active Ceased
-
2025
- 2025-06-10 US US19/233,420 patent/US20250319174A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9109011B2 (en) | Dendritic cell-specific antibody conjugate comprising anti-CD40 monoclonal antibodies conjugated to HIV-1 Gag/Nef | |
| JP2021517895A5 (https=) | ||
| JP2021517813A5 (https=) | ||
| JP2021138721A (ja) | Ｈｉｖ予備免疫化および免疫療法 | |
| Bachmann et al. | Maintenance of memory CTL responses by T helper cells and CD40‐CD40 ligand: antibodies provide the key | |
| JP2022101658A (ja) | Ｈｉｖワクチン接種および免疫療法 | |
| IL277188B2 (en) | Intracellular delivery of biomolecules to modify the immune response | |
| JPWO2019178005A5 (https=) | ||
| RU2013106217A (ru) | Гибридный белок из антитела против мнс и противовирусного цитокина | |
| JPWO2019178006A5 (https=) | ||
| JP2019531293A (ja) | Ｐｄ−１ペプチド阻害剤 | |
| Arribillaga et al. | Bivalent therapeutic vaccine against HPV16/18 genotypes consisting of a fusion protein between the extra domain A from human fibronectin and HPV16/18 E7 viral antigens | |
| JP2021515588A5 (https=) | ||
| JPWO2022147026A5 (https=) | ||
| Schmidt et al. | Rational design and in vivo characterization of vaccine adjuvants | |
| Carnathan et al. | Harnessing activin A adjuvanticity to promote antibody responses to BG505 HIV envelope trimers | |
| JPWO2019145509A5 (https=) | ||
| Yuan et al. | Divergent primary immune responses induced by human immunodeficiency virus-1 gp120 and hepatitis B surface antigen determine antibody recall responses | |
| JPWO2022147443A5 (https=) | ||
| Murali-Krishna et al. | An Evaluation of Bystander Activation in Primary and Secondary Responses to Viral Infection | |
| AU2012202953B2 (en) | HIV vaccine based on targeting maximized Gag and Nef to dendritic cells | |
| JPWO2022051437A5 (https=) | ||
| Cecil et al. | Structure and immunogenicity of alternative forms of the simian immunodeficiency virus gag protein expressed using Venezuelan equine encephalitis virus replicon particles | |
| CN117645673A (zh) | 一种IL-21与sCD4及Fc的融合蛋白及其应用 | |
| Half-life | P34. 08 Strain Specific Anti-HIV Antibody Evolution during Acute Infection and Viral Escape |